Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TMB-H
i
Other names:
TMB | Tumor Mutational Burden
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
(186)
News
Trials
Search handles
@ACortelliniMD
@AaronGoodman33
@Amitmahipal79
@AndreaNecchi
@AndresFCardonaZ
@ArndtVogel
@AshleySumrallMD
@AuclairDan
@AzadOncology
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BradMcG04
@C_Ricordel
@CarmenCalfa
@CathyEngMD
@ChrisHeery
@DocCatenacci
@DrBonillaOnc
@DrDanielHeng
@DrJNaidoo
@DrMMurphy
@DrMarkAwad
@DrR_DUNNE
@DrSteveMartin
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GeneCollector
@GeorgeSledge51
@Jaskirat__SR
@JavleMilind
@LGerratana
@MARIANOPROVENCI
@MPishvaian
@MVanMeterMD
@ManuelDomine
@Martin_AngelMD
@MichalisLiontos
@MiteshBorad
@MridulaGeorgeMD
@Myeloma_Doc
@NamBuiMD
@NicoleKuderer
@OmidHamidMD
@OncoLucus
@RachelRiechelm2
@RenoHemonc
@RielyMD
@SalemGIOncDoc
@StephenVLiu
@TaylorJ_MD
@TejasPatilMD
@TiansterZhang
@Tony_Calles
@VivekSubbiah
@aftimosp
@alantanmd
@bpiperdi
@cancerassassin1
@christine_lovly
@davidhenrymd
@dr_yakupergun
@drymtn
@hemedoc
@jamecancerdoc
@jgong15
@jonathanloree
@jsoriamd
@kevinpunie
@koshkin85
@marklewismd
@mtmdphd
@naborala
@nataliagandur
@oncoOuLungCA
@pashtoonkasi
@realbowtiedoc
@rschilsky
@sepideh_gholami
@sonpavde
@stolaney1
@teamoncology
@tompowles1
Search handles
@ACortelliniMD
@AaronGoodman33
@Amitmahipal79
@AndreaNecchi
@AndresFCardonaZ
@ArndtVogel
@AshleySumrallMD
@AuclairDan
@AzadOncology
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BradMcG04
@C_Ricordel
@CarmenCalfa
@CathyEngMD
@ChrisHeery
@DocCatenacci
@DrBonillaOnc
@DrDanielHeng
@DrJNaidoo
@DrMMurphy
@DrMarkAwad
@DrR_DUNNE
@DrSteveMartin
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@FawziAbuRous
@FogacciJoao
@FordePatrick
@GeneCollector
@GeorgeSledge51
@Jaskirat__SR
@JavleMilind
@LGerratana
@MARIANOPROVENCI
@MPishvaian
@MVanMeterMD
@ManuelDomine
@Martin_AngelMD
@MichalisLiontos
@MiteshBorad
@MridulaGeorgeMD
@Myeloma_Doc
@NamBuiMD
@NicoleKuderer
@OmidHamidMD
@OncoLucus
@RachelRiechelm2
@RenoHemonc
@RielyMD
@SalemGIOncDoc
@StephenVLiu
@TaylorJ_MD
@TejasPatilMD
@TiansterZhang
@Tony_Calles
@VivekSubbiah
@aftimosp
@alantanmd
@bpiperdi
@cancerassassin1
@christine_lovly
@davidhenrymd
@dr_yakupergun
@drymtn
@hemedoc
@jamecancerdoc
@jgong15
@jonathanloree
@jsoriamd
@kevinpunie
@koshkin85
@marklewismd
@mtmdphd
@naborala
@nataliagandur
@oncoOuLungCA
@pashtoonkasi
@realbowtiedoc
@rschilsky
@sepideh_gholami
@sonpavde
@stolaney1
@teamoncology
@tompowles1
Filter by
Latest
8ms
Is anyone studying SBRT + IO? Encouraged by the recent success of SBRT + atezo in early stage NSCLC- but not sure if the same biological rationale is present here (maybe in later line or high TMB NETs) @RachelRiechelm2 (@JohnEbbenMDPhD)
8 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
|
Tecentriq (atezolizumab)
8ms
🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)
8 months ago
Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • TMB-H • PD-L1 overexpression
|
Imfinzi (durvalumab)
9ms
Fascinating finding!! In advanced NSCLC, high TMB (esp TMB>20) associates w durable IO benefit but PDL1 high does not? Hopeful this tool could help to guide precision IO for NSCLC. Bravo @rohit_thum and @MSKCancerCenter @DanaFarber @MDAndersonNews colleagues! (@geoff_oxnard)
9 months ago
Metastases
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-H
9ms
Hi Dr. Ocean, What is considered a high TMB for pancreatic cancer? My mother's tumor genomic testing reported 5.3m/MB & 67th percentile. Is that considered high? thank you. (@pjmorrett)
9 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
10ms
Our new article explores the limited benefits of immune checkpoint inhibitors in MSS colorectal cancer patients with high TMB. https://t.co/gv4pOVODhL. Thank you @IbrahimSahinMD1 for the opportunity and guidance. (@CharanVegivinti)
10 months ago
Clinical • Checkpoint inhibition
|
TMB (Tumor Mutational Burden)
|
TMB-H
10ms
So is this only for NSCLCs that are hot tumors with high TMB? Or also for oncogene-driven? (@LauraJBook)
10 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
10ms
Validation of high #TMB as a biomarker of benefit with single agent #IO in #pancreatic cancer Small but important cohort @UHhospitals @caseccc @doctorC369 @TedTeknosMD #asco2023 (@Amitmahipal79)
10 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
10ms
You may be right that it shouldn't be rushed, but I'm kinda glad it was. For me, high TMB was the only way to Keytruda, as I'm MMRp and PD-L1 neg with mTNBC. 6th line of treatment - something had to work! 16 mos and counting! 🙂 (@DeaneDubois)
10 months ago
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
TMB-H
|
Keytruda (pembrolizumab)
10ms
So honored to mentor 🤩 @VUMCMedicineRes @VUMC_Cancer fellow @EricLanderMD . He gave a GREAT presentation on our collaboration with @NateraOncology noting: ⬆️ Her-2 and ⬆️ Her-3 in MSI-H #earlyonset #colorectal #cancer ⬆️ MSS/TMB-high w/ ⬆️ POLE MT ⬆️ ACVR2A Vs avg age onset… https://t.co/uEPgKiYtkb (@CathyEngMD)
10 months ago
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
10ms
So honored to mentor 🤩 @VUMCMedicineRes @VUMC_Cancer fellow @EricLanderMD . He gave a GREAT presentation on our collaboration with @NateraOncology noting: ⬆️ Her-2 and ⬆️ Her-3 in MSI-H/TMB high #earlyonset #colorectal #cancer ⬆️ MSS/TMB-high w/ ⬆️ POLE MT ⬆️ ACVR2A Vs avg age… https://t.co/V8XX1P4zS4 (@CathyEngMD)
10 months ago
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ACVR2A (Activin A Receptor Type 2A)
|
TMB-H • MSI-H/dMMR
11ms
Amazing molecular tumor #MTB board in #GUcsm with @FoundationATCG Two ✌️ interesting cases ➡️ Penile carcinoma 🧬high TMB & BRCA & HER2 amplification....What to do?? By @fedelosco ➡ Prostate cancer 🧬HRR mutation in MRE11A. Does iPARP work?. By me @fundacion_FUCA @IAF_Fleming (@Martin_AngelMD)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset) • MRE11A (MRE11 homolog, double strand break repair nuclease)
|
TMB-H • HER-2 amplification • MRE11A mutation
11ms
Great talk by Dr. Loibl on ICI in early stg TNBC 📌 low TMB tumors had greater benefit w Durvalumab compared to high TMB 📌 do we need anthracylc in TNBC in the era of IO TX ➡️ geparBOOG study ongoing 📌 ?role of adjuvant ICI s/p neoadj ICI. ➡️GeparDouze #ESMOBreast23 @OncoAlert (@MridulaGeorgeMD)
11 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H • TMB-L
|
Imfinzi (durvalumab)
11ms
To add to this excellent thread, not all POLE mutations = high #TMB as you may notice on #NGS report - most pathogenic #POLE mutations that lead to ultra-mutated #crcsm #MSS phenotype cluster around the active DNA-binding sites of the exonuclease proofreading domain (@jgong15)
11 months ago
Next-generation sequencing
|
TMB (Tumor Mutational Burden) • POLE (DNA Polymerase Epsilon)
|
TMB-H • POLE mutation
11ms
💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/0szeSSwAoc (@nataliagandur)
11 months ago
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
11ms
💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/fD1GFRle4v (@nataliagandur)
11 months ago
Clinical • Clinical data • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase)
|
BRCA2 mutation • TMB-H • ATM mutation • BRCA2 mutation + ATM mutation
11ms
TMB-h in #NETCancer predicts response to immunotherapy? Favorable response to immunotherapy in TMB-h G3 #NETCancer doi: 10.1002/cac2.12114 doi: 10.1200/PO.22.00009 (@RachelRiechelm2)
11 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
We really don’t know. … we have seen high TMB for pts whose #NETCancer harbor pathogenic Germline variants in MUTHY @gitorrezan (@RachelRiechelm2)
11 months ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
11ms
Treatment for KRAS G12C Mutated NSCLC with High Tumor Mutational Burden ... https://t.co/qGKggDWoZg via @YouTube n this video Drs. @IbiayiMD, Kathryn Arbour, and @NIVokes discuss treatment options for patients who have KRAS G12C Mutated NSCLC and a high tumor mutational burden. (@cancerGRACE)
11 months ago
Clinical • Video • Tumor mutational burden
|
KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
|
KRAS mutation • TMB-H • KRAS G12C • KRAS G12
11ms
2/8 We identified 562 deleterious ATM mutations in 9.7% (503/5172) of NSCLC samples. ATM mutations were associated with high TMB, increased PD-L1 expression and were enriched in KRAS, STK11, and ARID2 co-mutations. TP53 and EGFR mutations were enriched in ATM wild-type NSCLCs. (@BiagioMd)
11 months ago
IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ATM (ATM serine/threonine kinase) • STK11 (Serine/threonine kinase 11) • ARID2 (AT-Rich Interaction Domain 2)
|
PD-L1 expression • TP53 mutation • KRAS mutation • EGFR mutation • TMB-H • ATM mutation • STK11 mutation • KRAS mutation + STK11 mutation + TP53 mutation • KRAS expression
12ms
Penultimate day at #AACR2023! Take some time to stop by the posters and see our work on Pan-cancer analysis of XPO1 R749Q mutations reveals association with high TMB and therapeutic resistance #4253 (section 31, board 2) #CRCsm #GYNCsm #Cancer #CancerResearch (@TaylorJ_MD)
12 months ago
IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • XPO1 (Exportin 1)
|
TMB-H • XPO1 R749Q • XPO1 mutation
12ms
Desmoplastic melanomas have lot of UV damage and high TMB , not a big surprise .. (@RenoHemonc)
12 months ago
TMB (Tumor Mutational Burden)
|
TMB-H
12ms
#ctDNA profiling of bTMB and copy number burden (bCNB) can predict poor outcomes in patients with #metastatic #BreastCancer treated with ET and CDK4/6i. Dominant APOBEC signatures were detected at baseline in cases with high bTMB. #bcsm #PrecisionMedicine https://t.co/W2sYZ1ij4Q (@LGerratana)
12 months ago
Clinical • Tumor mutational burden • Circulating tumor DNA • Metastases
|
TMB (Tumor Mutational Burden) • CDK4 (Cyclin-dependent kinase 4)
|
TMB-H
12ms
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden https://t.co/cxIhSqikK1 (@AndresFCardonaZ)
12 months ago
Clinical • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
12ms
🔥Tumor mutational burden as a biomarker in patients with MSI #colorectalcancer treated with immune checkpoint inhibitors @OncologyAdvance https://t.co/YWWhyJ7ExW 🔎🇮🇹RWD 110 pts 👉low TMB -> cold tumors -> poor outcome 👉high TMB -> max benefit with anti-PD-1/CTLA-4 @myESMO… https://t.co/GPuu1CFTem (@ArndtVogel)
12 months ago
Clinical • Checkpoint inhibition • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden)
|
TMB-H • TMB-L
12ms
As a Sg 4 NSCLC BRAF v600e dx 8/2019, so much to appreciate here, esp the patient section! I'm back on pembro after a year's break followed by progression. Appear to be responding well (PD-L1 neg but high TMB). 🤍how pt emphasizes hope for others. #includeus (@AlysonH70982913)
12 months ago
Clinical
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
|
BRAF V600E • TMB-H
|
Keytruda (pembrolizumab)
1year
He’s a 10 but he’s a misleading tumor mutational burden (@HJLenz59 argues for a MUCH higher TMB threshold for response prediction to IO in mCRC) @CMECedarsSinai @DrHendifar @jgong15 @PamelaKunzMD #crcsm (@marklewismd)
1 year ago
Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Not all TMB-high are created equal & predict for #immunotherapy efficacy. In GI cancers with MSS & TMB-high, mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, & RASA1 were associated with suppressed tumor immune environment. https://t.co/YtBonLmOZs (@jsoriamd)
1 year ago
Clinical • IO biomarker
|
TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • mTOR (Mechanistic target of rapamycin kinase) • RASA1 (RAS P21 Protein Activator 1) • SMAD2 (SMAD Family Member 2)
|
TMB-H • MTOR mutation
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study https://t.co/bu1wdy9Ags (@JavleMilind)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study @TheLancetOncol https://t.co/6CWo26E0SX (@VivekSubbiah)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Discussion across GU malignancies to start day at #GU23 Biomarkers of response to Enfortumab Vedotin in UC, cabo/nivo in RCC, updated analysis of nivo/ipi of CRPC - high TMB not predictive of benefit and new clinical risk stratification for relapse in stage 1 seminoma @OncLive (@BradMcG04)
1 year ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Padcev (enfortumab vedotin-ejfv)
1year
The Oral abstracts have started #GU23! Biomarkers for urothelial cancer! High TMB good in EV treated patients. This was a great talk. @OncoAlert @ASCOPost (@DrDanielHeng)
1 year ago
Clinical
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
UNITE: Biomarkers for EV in pts with advanced UC #GU23 @urotoday 📌 n=170 📌 Longer OS with high TMB 📌 Shorter PFS for CDKN2A, CDKN2B or MTAP alterations (@zklaassen_md)
1 year ago
Clinical • Metastases
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TMB-H
1year
Please join us in Oral Testis/Penile abstract session #GU23 we will present features of #penilecancer with high TMB, including the original germline mutation frequencies @SpiessPhilippe @FoundationATCG @MyUniSR @urotoday @ASCO @GTumors (@AndreaNecchi)
1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Excellent perspective on issue we face in our MDT on pts w/“high” & MSS…more than meets the 👁️ as we delve deeper into NGS. Mutational analysis of microsatellite-stable GI cancer with high tumour mutational burden: a retrospective cohort study https://t.co/IZ5c2ObKSs (@drymtn)
1 year ago
Retrospective data • Next-generation sequencing • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
🔥Mutational analysis of MSS GI cancer with TMBhigh @TheLancetOncol https://t.co/4RWhL2SfYF ✅48606 pts CARIS 👉MSS/TMB-H 3.3% 👉Distinct genomic profile relevant for IO 👉mTMB gene signature for IO efficacy 👉 CCND1, FGF, HER2 CNV ⬆️ -> combination💊? @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical • Gene Signature
|
HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CCND1 (Cyclin D1) • FGF (Fibroblast Growth Factor)
|
TMB-H
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study - The Lancet Oncology https://t.co/BKmyRWsyrR (@jonathanloree)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
No activity of anti-PD-1 monoRx in mCRPC in unselected pts, no enrichment for high-TMB or MSI-H, highly active control arm....the odds were always stacked against this trial sadly. Another negative immunotherapy trial in #ProstateCancer ...... (@AzadOncology)
1 year ago
Clinical
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
1year
Not surprising but a disappointment. Still, make sure to test all metastatic prostate cancer patients for MSI-H and TMB-H as pembrolizumab is active and is standard care in prostate cancers with these rare phenotypes (~5% of our patients). (@DSolit)
1 year ago
Clinical • Metastases
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR
|
Keytruda (pembrolizumab)
1year
Mutational analysis of MSS GI cancer with high TMB: 💥Not all mutations related to TMB-H can enhance antitumour immune response 💥Although TMB is low, some mutations increase the immune response ❗Attention should be paid to the function of mutations https://t.co/nGPF2yLvUb (@dr_yakupergun)
1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study - The Lancet Oncology https://t.co/JirJeZzp1E (@ChrisHeery)
1 year ago
Retrospective data • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Happening now @ASCO #GI23 poster session. @AnwaarSaeed3 presents a study of colorectal patients with Microsatellite Stable disease with high Tumor Mutation Burden (TMB). Level 1 West Hall Poster #N11 (@UPMCHillmanCC)
1 year ago
Clinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden)
|
TMB-H
1year
Check out our poster on high TMB in MSS CRC at #GI23 @ASCO love this collaborative group! @AnwaarSaeed3 @cancerassassin1 @mgfakih @jonathanloree @skopetz @MayCho_MD @NorthwellHealth @CSHL @MDAndersonNews @CCAlliance @FightCRC @UPMCHillmanCC (@sepideh_gholami)
1 year ago
TMB (Tumor Mutational Burden)
|
TMB-H
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login